BioInvent International 将来の成長

Future 基準チェック /66

BioInvent International利益と収益がそれぞれ年間62%と55.6%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に45.6% 53%なると予測されています。

主要情報

62.0%

収益成長率

53.0%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	55.6%
将来の株主資本利益率	45.6%
アナリストカバレッジ	Low
最終更新日	n/a

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

OTCPK:BOVN.F - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2024	226	-72	N/A	N/A	2
12/31/2023	47	-312	N/A	N/A	2
12/31/2022	194	-109	N/A	N/A	2
6/30/2022	295	-42	-289	-276	N/A
3/31/2022	30	-266	-290	-276	N/A
12/31/2021	19	-278	-259	-246	N/A
9/30/2021	113	-171	-153	-141	N/A
6/30/2021	126	-141	-123	-115	N/A
3/31/2021	137	-123	-85	-78	N/A
12/31/2020	147	-76	-69	-63	N/A
9/30/2020	74	-146	-125	-119	N/A
6/30/2020	76	-150	-117	-112	N/A
3/31/2020	93	-144	-124	-120	N/A
12/31/2019	94	-139	-129	-125	N/A
9/30/2019	79	-130	-139	-136	N/A
6/30/2019	68	-116	-152	-148	N/A
3/31/2019	45	-126	-156	-152	N/A
12/31/2018	39	-123	-145	-141	N/A
9/30/2018	42	-124	-136	-126	N/A
6/30/2018	42	-123	-128	-116	N/A
3/31/2018	43	-103	-112	-99	N/A
12/31/2017	45	-101	-92	-76	N/A
9/30/2017	62	-75	-87	-76	N/A
6/30/2017	56	-82	-85	-75	N/A
3/31/2017	55	-85	-89	-81	N/A
12/31/2016	71	-63	-77	-72	N/A
9/30/2016	50	-76	-64	-59	N/A
6/30/2016	51	-70	-48	-46	N/A
3/31/2016	45	-69	N/A	-50	N/A
12/31/2015	16	-91	N/A	-73	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BOVN.Fは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2% ) よりも高い成長率であると考えられます。

収益対市場: BOVN.F今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: BOVN.F今後 3 年以内に収益を上げることが予想されます。

収益対市場: BOVN.Fの収益 ( 55.6% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: BOVN.Fの収益 ( 55.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BOVN.Fの自己資本利益率は、3年後には非常に高くなると予測されています ( 45.6 %)。

BioInvent International 将来の成長

Future 基準チェック /66

主要情報

今後の成長に関する最新情報

Recent updates

BioInvent International AB (publ) to Report Q3, 2025 Results on Oct 29, 2025

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

Bioinvent International AB Announces the Enrollment of the First Patient in Triple Combination Arm of Phase 1/2A Study, Bi-1206, Rituximab and Calquence(R) for the Treatment of Non-Hodgkin's Lymphoma

Bioinvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program

BioInvent Receives Notice of Allowance from USPTO for BI-1910 Patent Application

Bioinvent International AB Presents Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Agent BI-1808 At PAGE 2024

BioInvent International Gains Patent for BI-1808 in China

BioInvent International AB Presents Promising Clinical Efficacy and Safety for Anti-Tnfr2 Agent BI-1808 At Asco 2024

Bioinvent to Present Additional Promising Phase 1/2A Data At EHA 2024 for BI-1206 with rituximab in NHL

BioInvent International AB (publ) to Report Nine Months, 2024 Results on Oct 31, 2024

BioInvent International AB (publ), Annual General Meeting, May 03, 2024

BioInvent International AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024

BioInvent International AB (publ) Presents Positive First Clinical Data on Anti-FcyRIIB Antibody BI-1607

Bioinvent Enrolls First Patient in Phase 1/2A Clinical Trial with TNFR2 Antibody BI-1910

BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial of BI-1808 as Single Agent

BioInvent Presents Preclinical Data at SITC Providing Clear Evidence of the Potential of Anti-TNFR2 Antibody BI-1910

Bioinvent International AB Recruits First Patient in Single Agent Phase 2a Part of its Phase 1/2a Trial of its First-in-Class Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies

BioInvent International AB Initiates Subcutaneous Arm of Phase 1/2 Trial with BI-1206 in Solid Tumors

BioInvent International AB (publ) Reports Strong Interim Safety Data and Early Signs of Efficacy in Phase 1/2a Trial with Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies

BioInvent International AB Announces Abstract Presentation of BI-1206 At the 17th International Conference of Malignant Lymphoma 2023

BioInvent International AB Announces Additional Efficacy Data from Intravenous Part of Phase 1/2 Trial with BI-1206 in Solid Tumors

BioInvent Ready for Combination Studies with BT-001

BioInvent International AB (Publ) Appoints of Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs

BioInvent International AB (publ), Annual General Meeting, Apr 27, 2023

Bioinvent International AB Provides Update on Its Clinical and Pre-Clinical Pipeline, Including an Update on Its Lead Drug Candidate, the Novel Anti-Fc?RIIB Antibody Bi-1206

BioInvent International AB (publ) Receives FDA IND Approval for Anti-FcyRIIB Antibody BI-1607

BioInvent International AB (publ) Completes Dose Escalation Part of the Phase I/IIa Study with Anti-TNFR2 Drug Candidate BI-1808

CASI Pharmaceuticals and BioInvent Announces Dosing of First Patient in BI-1206 Phase 1 Clinical Trial for the Treatment of Relapsed/Refractory Non-Hodgkin's Lymphoma in China

BioInvent International AB (publ) to Report Q2, 2023 Results on Aug 30, 2023

BioInvent International AB (publ) to Report Q1, 2023 Results on Apr 26, 2023

BioInvent International AB (publ) Enrolls First Patient in Phase 1/2A Trial of Bi-1607 in HER2 Positive Solid Tumors

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘